In our most recent poll, we asked users if they would alter use of prasugrel and ticagrelor based on the results of the ISAR REACT-5 trial (Intracoronary Stenting and Antithrombotic Regimen 5). The responses were relatively evenly split. Approximately one third of respondents indicated that their use of prasugrel would substantially increase, one third indicated that they would slightly increase their use of prasugrel, and one third indicated that they planned no significant change in the use of the two agents.

Keywords: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Anticoagulants, Fibrinolytic Agents, Stents

< Back to Listings